Aeterna Neovastat Will Be 12th Antiangiogenesis Drug To Reach Phase III
Executive Summary
Aeterna Labs' Neovastat will begin patient enrollment for a Phase III clinical trial in non-small cell lung cancer in March, CEO Eric Dupont reported Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.
You may also be interested in...
Signal Chooses Acquisition By Celgene Over Initial Public Offering
Signal Pharmaceuticals has chosen to accept an acquisition offer from Celgene instead of going through with an initial public offering, the companies said in a June 30 analysts call announcing the merger.
Signal Chooses Acquisition By Celgene Over Initial Public Offering
Signal Pharmaceuticals has chosen to accept an acquisition offer from Celgene instead of going through with an initial public offering, the companies said in a June 30 analysts call announcing the merger.
Oncologic Drug QoL Data Useful After Treatment Failure - FDA Cmte.
Quality of life assessments should be collected even after treatment failure, a subcommittee of FDA's Oncologic Drugs Advisory Committee suggested at a Feb. 10 meeting in Bethesda, Md.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: